<DOC>
	<DOCNO>NCT02393287</DOCNO>
	<brief_summary>The objective observatory evaluate effecacy Eribulin patient metastatic breast cancer recent prescription period . Part data collection retrospective part prospective patient start treatment Eribulin November 2014 September 2015 . It allow well assessment safety profile drug .</brief_summary>
	<brief_title>Retroprospective Real Life Observatory Eribulin</brief_title>
	<detailed_description>Approximately one third patient treat localized breast cancer present metastatic evolution 5 % patient metastatic immediately . At stage , malignancy incurable median survival 2 3 year . Metastatic breast cancer treatment part multidisciplinary approach . These two objective prolong survival improve quality life . At present , standard first line chemotherapy , fe strategy study Eribulin new therapeutic option consider . Many patient benefit treatment option seem interesting evaluate real life effecacy tolerance chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Age â‰¥ 18 year 2 . Patient breast cancer , histologically proven , metastatic locally advance 3 . Patient treat Eribulin January October 2014 ( retrospective part ) November 2014 September 2015 ( prospective part ) . 4 . Patient least assessment response Eribulin 1 . Presence neoplasia 2 . Man</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>